Overview

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

Status:
Terminated

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

PF-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce vascular permeability. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and effects on histamine-induced wheal of single doses of PF-05180999 in healthy adult subjects. Histamine-induced wheals are biomarkers of vascular permeability.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Cetirizine
Histamine
Histamine phosphate